Global drugmakers refusing to conduct clinical trials in Russia

Due to Russia’s military invasion of the Ukraine, global pharma companies are massively refusing to conduct clinical trials of their drugs in Russia, which means that the launch of these drugs in the local market will be impossible or at least seriously delayed, reports The Pharma Letter’s local correspondent.

So far, these plans have been confirmed by representatives of Pfizer (NYSE: PFE), Eli Lilly, AbbVie (NYSE: ABBV), Sanofi (Euronext: SAN) and Merck & Co (NYSE: MRK), as well as other companies.

For example, Pfizer, whose sales in Russia for 2021 according to data of the local analytical company DSM Group amounted to 52.8 billion roubles (~$496 million), said that it would transfer all current clinical trials to alternative sites outside of Russia.